Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
Smith MR, Jegede O, Martin P, Till B, Parekh S, Yang DT, Hsi ED, Witzig TE, Dave SS, Scott DW, Hanson CA, Kostakoglu L, Abdel Samad NN, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum K, Romer M, Inwards DJ, Lerner R, Wagner L, Little RF, Friedberg JW, Leonard JP, Kahl BS.
Smith MR, et al. Among authors: yang dt.
Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962. Online ahead of print.
Blood. 2024.
PMID: 38820500